CM
FULC icon

Caption Management’s Fulcrum Therapeutics FULC Stock Holding History

Caption Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,204,300
Closed -$4.3M – 1588
2024
Q3 		$4.3M Buy
1,204,300
+994,300
+473% +$7.38M 0.07% 335
2024
Q2 		$1.3M Buy
210,000
+105,500
+101% +$799K 0.02% 594
2024
Q1 		$986K Buy
+104,500
New +$933K 0.02% 739

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caption Management's FULC Position: Q4 2024 in Review

Caption Management sold out of Fulcrum Therapeutics (FULC) in Q4 2024, closing a stake of 307,414 shares — an estimated $1.13M sold.

Caption Management first reported a position in FULC in Q1 2022 and held it in 4 quarters. The position peaked at $3.26M in Q2 2024. 119 funds tracked by Wall St. Rank hold FULC as of Q4 2024.

  • Caption Management reported no remaining Fulcrum Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Caption Management sold 307,414 Fulcrum Therapeutics shares in Q4 2024, an estimated $1.13M.
  • Caption Management first reported a position in Fulcrum Therapeutics in Q1 2022 and held it in 4 quarters.
  • Caption Management's Fulcrum Therapeutics position peaked at $3.26M in Q2 2024.
  • 119 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2024.

Based on Caption Management's 13F filing for Q4 2024, filed 14 Feb 2025.